Diabetes drugs have come a long way from meta-analyses from Steven Nissen, chairman of cardiovascular medicine at the Cleveland Clinic, and others suggesting that Avandia (rosiglitazone, Glaxosmithkline plc) was increasing the risk of cardiovascular (CV) problems.